Capricor Therapeutics announced the pricing of its underwritten public offering of 6,000,000 shares of common stock at $25.00 per share, with an option for additional shares.
The offering is expected to close on or about December 8, 2025.
The gross proceeds from the offering are expected to be $150 million.
Underwritten Public Offering
6,000,000 shares priced at $25.00 per share with potential additional shares.
Underwriters
Piper Sandler and Oppenheimer & Co. are the joint book-running managers; H.C. Wainwright & Co. is the co-manager.
Net Proceeds
Intended for product candidate development, manufacturing, working capital, and general corporate purposes.
- The offering provides Capricor Therapeutics with substantial funding for its product development and corporate activities.
- The participation of reputable underwriters enhances investor confidence in the company's prospects.
With the successful pricing of the public offering and strong underwriting support, Capricor Therapeutics is poised for significant progress in its transformative therapeutics development.